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ABSTRACT
Objective: To estimate the tobacco-attributable costs of
diseases separately for smoked and smokeless tobacco
use in India.
Methods: The prevalence-based attributable-risk
approach was used to estimate the economic cost of
tobacco using healthcare expenditure data from the
National Sample Survey, a nationally representative
household sample survey conducted in India in 2004. Four
major categories of tobacco-related disease—tuberculo-
sis, respiratory diseases, cardiovascular diseases and
neoplasms—were considered.
Results: Direct medical costs of treating tobacco related
diseases in India amounted to $907 million for smoked
tobacco and $285 million for smokeless tobacco. The
indirect morbidity costs of tobacco use, which includes
the cost of caregivers and value of work loss due to
illness, amounted to $398 million for smoked tobacco and
$104 million for smokeless tobacco. The total economic
cost of tobacco use amounted to $1.7 billion. Tuberculosis
accounted for 18% of tobacco-related costs ($311 million)
in India. Of the total cost of tobacco, 88% was attributed
to men.
Conclusions: The cost of tobacco use was many times
more than the expenditures on tobacco control by the
government of India and about 16% more than the total
tax revenue from tobacco. The tobacco-attributable cost
of tuberculosis was three times higher than the
expenditure on tuberculosis control in India. The economic
costs estimated here do not include the costs of
premature mortality from tobacco use, which is known to
comprise roughly 50% to 80% of the total economic cost
of tobacco in many countries.
Knowledge of the health consequences of tobacco
use has led to much greater reductions in tobacco
use in developed than in developing countries. The
tobacco epidemic is estimated to kill 8 million
people annually, with 80% of deaths in developing
countries by 2030.
1 Smoking related medical costs
account for 6% to 15% of healthcare costs in high-
income countries.
2 Evidence from developing coun-
tries such as China and Vietnam place this
estimate around 4%.
34
With roughly 10% of the world’s smokers, India
is the second largest consumer of tobacco in the
world,
1 second only to China. Tobacco consump-
tion in India is characterised by a large proportion
of non-cigarette and smokeless tobacco use.
Manufactured cigarettes constitute only 14% of
the tobacco consumption in India.
5 The health
effects of non-cigarette tobacco use are under-
researched probably because they are not popular
in most of the developed world. There is reason to
believe that the non-cigarette tobacco used in India
is also associated with significant adverse health
outcomes. Bidis, an indigenous and popular
smoked tobacco product in India, delivers nicotine,
carbon monoxide and other toxic components of
tobacco smoke in equal or greater amounts than
conventional cigarettes,
6 making bidi smoking a
stronger risk factor than cigarette smoking for
cancer of the hypopharynx and supraglottis.
7
Many of the smokeless tobacco products in India
such as Khaini, Mawa, Pan, Zarda and Gutkh are
also found to be risk factors for cancer.
7 Chewing
tobacco in India is also a risk factor for oral cancers
and esophageal cancers.
8 A recent nationwide
study on smoking and mortality in India estimated
that cigarette and bidi smoking causes about 5% of
all deaths in women and 20% of all deaths in men
aged 30–69 years, totalling 1 million deaths per
year in India in 2010.
9
There has been no comprehensive national level
study that estimated the economic cost of tobacco
use in India. However, a report submitted to the
government of India
10 referred to a study by Rath
and Chaudhry
11 that estimated the cost of three
major tobacco related diseases in India: cancer,
coronary artery disease and chronic obstructive
pulmonary disease. Based on a sample from 2
Indian locations—195 patients in Delhi and 500
patients in Chandigarh—they collected data on
treatment expenditures (medical and non-medi-
cal), institutional expenditures and loss of wages
during treatment for 1990–1992, or until death or
recovery. Using the consumer price index, they
estimated the total direct and indirect cost due to
three major tobacco related diseases in India in
1999 to be Rs.277.61 ($6.2) billion, 83.7% of which
was due to premature death. Reddy and Gupta
12
updated these costs to 2002–2003, estimating the
total cost for the three major tobacco related
diseases to be Rs.308.33 ($6.6) billion.
Because tobacco use causes more than just the
three diseases listed above, a more comprehensive
estimate of the economic burden of tobacco use in
India is needed. Moreover, the data needs to be
recent and representative to the nation as a whole.
This paper estimates the economic burden of
tobacco use in India by considering four major
categories of tobacco-related disease—tuberculosis,
respiratory diseases, cardiovascular diseases and
neoplasms—using nationally representative data.
This provides the first ever estimate of the
economic cost of tobacco in India using nationally
representative data. This is also the first time
economic costs are estimated separately for
smoked and smokeless tobacco. Moreover, the
tobacco-attributable cost of tuberculosis, a disease
of major importance for India
13 is estimated for the
first time in India. Tobacco smoke is known to
increase the risk of tuberculosis.
14 15 Recent epide-
miological studies in India has also supported this
claim.
9
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We use the prevalence-based attributable-risk approach applied
to tobacco-related costs by Rice et al
16 for estimating the
economic burden of tobacco use. This approach measures the
value of resources used (direct costs) or lost (indirect costs) from
tobacco-caused diseases and deaths during a specified period of
time, regardless of the time of tobacco use onset. This method
of estimation is designed to measure the aggregate economic
burden imposed on society attributable to tobacco use. Using a
standard epidemiological formula, it determines the proportion
of excess costs that can be attributed to tobacco use and hence
preventable. We include only persons aged 35 years and older in
the analysis, since relative risks for the diseases considered were
available only for this age group.
Data sources
The primary data source for estimating the tobacco-attributable
medical cost was the ‘‘Morbidity, Health Care and the Condition
of the Aged’’,60th round of the National Sample Survey (NSS)
conducted during January to June 2004. It was a nationally
representative survey conducted by the National Ministry of
Health and Family Welfare (MOHFW). It collected the data on
utilisation and expenditures of private and public healthcare
services—inpatient hospitalisation during the 365 days prior to
the date of interview and outpatient visits during the 15 days
prior to interview—from 47 302 rural and 26 566 urban house-
holds in India. Expenditures from inpatient hospitalisation were
reported for each disease and visit separately. However, expendi-
tures on outpatient visits were reported as total per person
regardless of number of visits and ailments. In order to calculate
the average expenditure per ailment per outpatient visit we
computed average expenditures on outpatient visit for each
ailment using only those patients with only one visit and that
amount was imputed to the expenditures for the respective
ailments of those with multiple visits and ailments. These 15-day
averages were multiplied by 24.33 to get annual estimates. NSS
self-reported household expenditures were scaled up by a factor of
1.68 to reflect the difference between NSS estimates and India’s
national healthcare expenditures (expenditures by households,
other private and public sources.
17
Therelativerisk(RR)ofmortalityusedtoestimatethesmoking
attributable fraction was taken from a prospective 1992–1999
cohort study of 99 570 Mumbai adults aged 35 or older.
18 They
reported the RR, adjusted for age and socioeconomic status,
separately for smokeless tobacco users and smokers by gender and
disease categories. This is the only study that provides cause-
specific RR separately for smoked and smokeless tobacco by
gender, and thus is relevant in the Indian context where wide
disparities in tobacco use exists between genders.
19
The data source for estimating the prevalence of tobacco use
was the second National Family Health Survey (NFHS-2)
20
conducted by the International Institute for Population Sciences
in 1998–1999. The NFHS-2 sample represented more than 99%
of India’s population across all 26 states.
The population figure in India was taken from the estimated
mid-year population for 2004 as projected by the US Census
Bureau (http://www.census.gov/ipc/www/idb/tables.html),
and was estimated to be 175 million males and 170 million
females aged 35 and older.
Estimation of the smoking attributable fraction
The smoking attributable fraction (SAF) is the proportion of
expenditures on personal health services and morbidity costs
that can be attributable to smoked and smokeless tobacco use.
Persons were classified into three mutually exclusive categories:
(1) never smokers: those who have never used any tobacco, (2)
smokeless tobacco users: those who have used smokeless
tobacco only and (3) smokers: those who have used smoked
tobacco regardless of whether they also used smokeless tobacco
or not (15% of adult males and 1% of adult females used smoked
and smokeless tobacco). We estimated the SAF separately for
smokeless tobacco users and smokers using an epidemiological
formula derived from Lilienfeld and Lilienfield
21 for each of the
disease categories by gender and tobacco use type (equation 1).
Subscripts t, d and g indicate type of tobacco users, disease
category and gender, respectively. PN, PEc and PEs denote the
percentage of people who are never smokers, smokeless tobacco
users and smokers, respectively, with c and s denoting
smokeless and smoked tobacco. RRc and RRs denote the relative
risk of mortality for smokeless tobacco users and smokers,
respectively, compared to never smokers.
Estimation of economic cost
We considered three components of the economic cost of
tobacco use: (1) direct healthcare expenditures for inpatient
hospitalisation or outpatient visits, including surgeon’s fees,
medicines, diagnostic tests, bed charges, attendant charges,
medical appliances and ambulatory services; (2) expenditures
incurred for transportation other than ambulance and lodging
charge of caregivers; and (3) wage income lost to the whole
household due to inpatient hospitalisation or outpatient visits.
Items 2 and 3 comprise indirect morbidity costs. A fourth and
important component of the economic cost of tobacco is the
cost of premature deaths from tobacco use. Data were not
available to estimate this component of cost.
Tobacco-attributable direct healthcare expenditures (TAE)
are the product of total healthcare expenditure (THE) and the
SAF:
TAEtdg=THEtdg6SAFtdg=[PHtdg6QHtdg + PVtdg6QVtdg
624.33] 6POPg 6SAFtdg
Where PH is the average expenditure per inpatient hospita-
lisation, QH is the average number of hospitalisations per
person in 365 days, PV is the average expenditure per outpatient
visit and QV is the average number of outpatient visits per
persons for 15 days prior to the date of interview. POP is the
population aged .=35 in 2004.
The tobacco-attributable indirect morbidity cost (TAI) is the
product of total indirect morbidity expenditure (TIE) and the
SAF:
TAItdg=TIEtdg 6 SAFtdg=[(PHItdg + PHLtdg) 6 QHtdg +
(PVItdg + PVLtdg) 6QVtdg 624.33] 6POPg 6SAFtdg
Where PHI and PVI are the average expenditure on
transportation and caregivers per inpatient hospitalisation and
per outpatient visit, respectively; PHL and PVL are the average
income lost due to absence from work from inpatient
hospitalisation and outpatient visits.
RESULTS
SAFs for smoked and smokeless tobacco
Table 1 shows the prevalence of tobacco use and the relative
risks of mortality used in this paper. The prevalence of ever
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4.4% for males and females while the prevalence of ever
smokeless tobacco users was 20.7% and 18.8% for males and
females. Prevalence of smoking is less among women in India
due to social unacceptability
12 and is largely a cultural
phenomenon. The relative risks of mortality were slightly
higher for smokers than smokeless tobacco users but did not
differ much by gender or disease category, with the exception of
tuberculosis, which was especially high for female smokers.
Table 2 shows the SAF of tobacco use by type of tobacco user,
gender and disease category computed based on the data shown
in table 1 and equation 1. For smokers, the SAFs are
substantially lower for women than men for all disease
categories partly due to their low smoking prevalence. Cancer
and tuberculosis show the highest and the second highest
disease-specific SAFs respectively for men, while tuberculosis
has the highest disease-specific SAF for women. As for
smokeless tobacco users, the SAFs between men and women
are not much different. Combining smoked and smokeless
tobacco use, the SAFs among men range from 22.8% for
cardiovascular diseases to 43.2% for neoplasms. Considering
that the SAFs among women are up to 22.6% for tuberculosis
and 12.6% for neoplasms, tobacco use contributes to a
significant proportion of the burden on Indian women’s health
despite the low prevalence of tobacco use among them.
The economic costs of tobacco use
Table 3 shows the economic cost of tobacco use for India in
2004 by disease, type of tobacco use and gender separately for
inpatient hospitalisation and outpatient visits. The top section
of table 3 shows TAEs. The total TAE of treating tobacco
related diseases amounted to $1192.5 million, including $833.9
million for male smokers, $73.2 million for female smokers,
$188.7 million for male smokeless tobacco users and $96.6
million female smokeless tobacco users. The TAEs were greater
for males than females for all disaggregated analyses except that
females have higher TAEs for treating cancer attributable to
smokeless tobacco use. The TAEs were highest for cardiovas-
cular diseases for males and females regardless of the type of
tobacco use. The total TAE from smoked tobacco ($907.1
million) was more than three times that from smokeless
tobacco ($285.3 million).
The middle and lower sections of table 3 show the tobacco-
attributable indirect morbidity costs for 2004. The total
tobacco-attributable transportation and caregiver costs
amounted to $91.3 million, including $64.7 million for male
smokers, $5.4 million for female smokers, $14.0 million for male
smokeless tobacco users and $7.1 million for female smokeless
tobacco users. Cardiovascular disease accounts for the largest
share of transportation and caregiver costs for males and
females. The total value of lost income from tobacco related
hospitalisation and outpatient visits amounted to $411.4
million, including $313.8 million for male smokers, $14.5
million for female smokers, $67.8 million for male smokeless
tobacco users and $15.3 million for female smokeless tobacco
users.
The last row of table 3 presents the total economic cost. Of
the total cost of $1.7 billion, smoked tobacco accounts for 77%
vs 23% for smokeless tobacco; 87% is attributed to males vs 13%
to females. Females contribute more to the cost of smokeless
tobacco (31%) than to smoked tobacco (7%). This is reflective of
the fact that the prevalence of smokeless tobacco use among
women is 19% compared to only 4% for smoked tobacco use.
DISCUSSION
This paper presents the first comprehensive estimate of the
economic burden of tobacco use at the national level for India.
The total economic cost of tobacco use in India for 2004
amounted to $1.7 billion, which is many times more than the
$551 876 that the government of India spent on tobacco control
activities in 2006,
1 and is 16% more than the total excise tax
revenues collected from all tobacco products in India in the
financial year 2003–2004 ($1.46 billion). Tobacco-attributable
direct costs ($1.2 billion) account for 4.7% of India’s total
national healthcare expenditure in 2004 ($25 billion).
17 In
comparison, studies from other developing countries such as
China
4 and Vietnam
3 found the direct cost of smoking to be
3.1% and 4.3% of the national healthcare expenditure,
respectively.
Tuberculosis is a major health risk in India with roughly 1.8
million new cases reported annually,
13 and our findings high-
light the important role of tobacco use for this disease. In fact,
tuberculosis accounts for $311 million (18%) of the total
economic cost of tobacco use in India, including $193 million
(16%) of the direct cost and $118 million (24%) of the indirect
morbidity cost. This is more than three times the $100 million
that was spent on tuberculosis control in India in the year
2006.
13
Table 1 Prevalence of tobacco use and disease-specific relative risk of
mortality from tobacco use in India by type of tobacco users and gender
for adults aged 35 and older
Smoked Smokeless
Male Female Male Female
Prevalence* (%) 42.3 4.39 20.65 18.84
Relative risk of death:
Respiratory diseases 2.12 1.15 1.50 1.04
Tuberculosis 2.30 5.92 1.46 1.40
Cardiovascular diseases 1.54 1.46 1.32 1.15
Neoplasm 2.60 1.85 1.40 1.57
*The prevalence of smokeless tobacco users includes those who only used smokeless
tobacco whereas prevalence for smokers includes some who also used smokeless
tobacco so that adding smoked and smokeless tobacco user would give prevalence
for any tobacco use.
Table 2 Disease-specific smoking attributable fractions (SAFs) (%) in India by type of tobacco use and
gender for adults aged 35 and older
Cause of death
Smoked Smokeless All tobacco*
Male Female Male Female Male Female
Respiratory diseases 30.04 0.65 6.55 0.74 36.59 1.39
Tuberculosis 33.43 16.73 5.77 5.84 39.21 22.56
Cardiovascular diseases 17.65 1.93 5.10 2.70 22.75 4.62
Neoplasm 38.47 3.26 4.69 9.38 43.16 12.64
*The SAF for all tobacco products equals the SAF for smokers plus the SAF for smokeless tobacco users.
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mortality to estimate the attributable morbidity. Risks of
morbidity and mortality from tobacco use need not be the same.
However, this approach has been widely used in the litera-
ture.
4 22–24 Two other approaches have been used to estimate the
SAFs for direct medical cost. One was originally developed by
Rice and Hodgson (1986),
16 in which the RR of healthcare
utilisation for smokers was first estimated and then applied to
the calculation of the SAFs for medical cost. The other one was
developed in the 1990s by several health economists,
25–27 in
which the SAFs was estimated directly from multiple-equation
econometric models of the impact of smoking on healthcare
expenditures. Due to our data limitations, we could not employ
either approach in this study. However, according to a study by
Rice and Hodgson,
16 the SAFs for direct medical cost estimated
by using the RR of healthcare utilisation approach was 23.5%,
while the SAFs for direct medical cost of smoking estimated by
using the RR of mortality approach was 19.7%. Therefore, the
use of RR of mortality as a proxy for RR of healthcare
utilisation is expected to yield an underestimated and con-
servative SAF for medical costs. Secondly, the relative risks we
used were taken from a cohort study of 99 570 persons in
Mumbai that is not nationally representative. Longitudinal data
on risk factors for healthcare expenditures would be required to
apply econometric models to cost estimation. With these data,
one could control for different risks, assess the source of
payments specifically for tobacco-related diseases and consider
the impact of cessation on healthcare expenditure.
Unfortunately these data are not available for India.
Our estimates are probably low. We were unable to include
the costs of premature mortality from tobacco use, because data
on number of deaths by underlying cause of death at the
national level in India are currently difficult to acquire.
However, the estimates presented here are still important
because it is the first time economic costs of tobacco use in India
are presented using nationally representative healthcare expen-
diture data. Even the conservative estimates presented here are
huge in comparison with the taxes collected from tobacco or the
expenditure on tobacco control incurred by Government of
India. The mortality cost has been estimated to account for 84%
of total tobacco-related costs in India.
11 Studies from China,
4
Korea,
28 USA,
29 and Germany
30 estimate the cost of premature
death to be 58%, 91%, 46% and 64% of the total cost of smoking
respectively. If the value of tobacco-attributable deaths adds
84% to the total costs, our estimate of the total economic costs
of tobacco use in India for 2004 would be $10.6 billion. It should
be also noted that due to the general assumptions used for
earnings and employment, the indirect costs especially for
women might be under-estimated. Furthermore, our analysis is
limited to four categories of tobacco-caused disease. Many more
diseases are known to be caused or exacerbated by tobacco use.
The huge healthcare burden attributable to tobacco use in
India has many dimensions. More than 70% of the healthcare
cost in India is out-of-pocket expenditures. Given that
consumption of tobacco in India is more prevalent among the
poor,
31 it is likely that much of the tobacco related illness and
the associated economic cost would also be higher among them.
Hospitalisations for tobacco related diseases force poor people
into debt traps and can result in severe impoverishment. There
is a higher risk (odds ratio 1.35) of borrowing and distress selling
during hospitalisation by individuals who use tobacco in India.
32
Expenditures on tobacco in India displace expenditures on food
and education.
33 Thus, high spending on tobacco coupled with
the higher healthcare burden of treating tobacco related diseases
can push tobacco consumers into a vicious circle of tobacco use,
ill health and poverty.
The economic cost of tobacco use in India reflects an
important gender dimension, with 87% costs accounted for by
males. Yet, the consequent toll on household income is shared
by all the household members. Tobacco control efforts should
take heed of these different dimensions of the economic costs of
tobacco use.
Current economic costs associated with tobacco use are much
higher than the tax revenues generated from tobacco. There is
also evidence that the taxes on tobacco in India are much lower
than the optimum level possible.
34 Hence, an increase in tobacco
taxes could be justified and that money could be used to pay for
tobacco induced healthcare expenditures for the poor and for
tobacco control efforts to prevent these diseases and lower these
costs. An increase in tobacco taxes can also reduce expenditures
on tobacco as increased taxes are known to result in decreased
tobacco use.
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